Placebo + fulvestrant

DRUG2 trials

Sponsors

Xuanzhu Biopharmaceutical Co., Ltd., Nanjing Chia-tai Tianqing Pharmaceutical

Conditions

Advanced Breast CancerHR Positive/HER2 Negative Advanced or Metastatic Breast Cancer

Phase 3

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Active, not recruitingNCT05077449

Xuanzhu Biopharmaceutical Co., Ltd.Advanced Breast Cancer

Start: 2021-11-16End: 2029-11-30Target: 300Updated: 2024-05-24

A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer

Not yet recruitingNCT07393321

Nanjing Chia-tai Tianqing PharmaceuticalHR Positive/HER2 Negative Advanced or Metastatic Breast Cancer

Start: 2026-02-10End: 2031-08-31Target: 210Updated: 2026-02-06

Related Papers

Abstract 7633: Dynamic monitoring and identification of reliable biomarkers to predict efficacy of bireociclib and fulvestrant: An exploratory ctDNA analysis of the BRIGHT-2 study

Cancer Research2026-04-03

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression

JAMA Oncology2026-03-19

Matching-adjusted indirect comparison of bireociclib plus fulvestrant versus abemaciclib plus fulvestrant as second-line treatment of HR+/HER2− advanced breast cancer.

Journal of Clinical Oncology2025-05-28

Brain metastasis incidence with bireociclib in HR+/HER2- advanced breast cancer: Pooled analysis of BRIGHT-1 and BRIGHT-2 study.

Journal of Clinical Oncology2025-05-28

Dynamic hematological indicators as predictors of CDK4/6 inhibitors efficacy in HR-positive, HER2-negative metastatic breast cancer.

Journal of Clinical Oncology2025-05-28

Abstract CT099: BRIGHT-2 final analysis: A phase III trial of bireociclib plus fulvestrant as second-line endocrine therapy for patients with advanced HR+/HER2-breast cancer

Cancer Research2025-04-251 citations

Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis

Nature Communications2025-04-091 citations

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Cancer Communications2025-02-273 citations

Bireociclib plus fulvestrant for advanced HR<sup>+</sup>/HER2<sup>-</sup> breast cancer progressing after endocrine therapy: Interim analysis of a phase 3 trial (BRIGHT-2).

Journal of Clinical Oncology2024-06-012 citations